Literature DB >> 20170363

Umbilical cord-derived mesenchymal stem cells isolated by a novel explantation technique can differentiate into functional endothelial cells and promote revascularization.

Yan Xu1, Hengxing Meng, Changhong Li, Mu Hao, Yafei Wang, Zhen Yu, Qian Li, Junling Han, Qiongli Zhai, Lugui Qiu.   

Abstract

Stem cells transplantation holds great promise for the treatment of ischemic diseases through functional revascularization. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are also an ideal candidate for cell-based bioengineering. Herein, we report on the development of a simple and effective protocol to isolate UC-MSCs, and confirm their endothelial potential both in vitro and in vivo. UC-MSCs were isolated by a novel explantation technique and induced to differentiate into endothelial-like cells. Then UC-MSCs were transplanted into ischemic mouse model and cultured on 3D gel/MMT-CS composite scaffolds. Morphological and proliferation assessments show that sufficient UC-MSCs can be generated during a relatively short culture period with explantation technique. Increased expression of endothelial-specific markers (KDR and vWF), and functional markers (ac-LDL uptake and UEA-1 binding), indicate that functional endothelial progenitor cells are induced after 9 days of in vitro culture. In an ischemic hindlimb mouse model, the ratio of ischemic/nonischemic limb perfusion 4 weeks after MSCs transplantation reached 0.84 +/- 0.09. The capillary density of this group was 2.57-fold greater than that of sham-injected mice (P < 0.05). Immunofluorescence and immunohistological analyses indicate that MSCs may act to salvage the ischemic tissue by incorporating into the local vasculature. In vitro, UC-MSCs were observed to incorporate into 3D gel/MMT-CS composite scaffolds, to secrete extracellular matrix, to remain viable, and to retain their proliferation capacity. In conclusion, UC-MSCs isolated by novel yet simple explantation technique are well suited for application in the development of novel stem cell-based revascularization therapies.

Entities:  

Mesh:

Year:  2010        PMID: 20170363     DOI: 10.1089/scd.2009.0321

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  20 in total

1.  Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells.

Authors:  Reine El Omar; Yu Xiong; Gabriel Dostert; Huguette Louis; Monique Gentils; Patrick Menu; Jean-François Stoltz; Émilie Velot; Véronique Decot
Journal:  Immunol Cell Biol       Date:  2015-10-29       Impact factor: 5.126

Review 2.  Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease.

Authors:  Luqia Hou; Joseph J Kim; Y Joseph Woo; Ngan F Huang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-12-18       Impact factor: 4.733

3.  Role of Nonmuscle Myosin II in Migration of Wharton's Jelly-Derived Mesenchymal Stem Cells.

Authors:  Sneha Arora; Shekhar Saha; Saheli Roy; Madhurima Das; Siddhartha S Jana; Malancha Ta
Journal:  Stem Cells Dev       Date:  2015-06-04       Impact factor: 3.272

4.  A mathematical model predicting the coculture dynamics of endothelial and mesenchymal stem cells for tissue regeneration.

Authors:  Yao Wang; Tomer Bronshtein; Udi Sarig; Evelyne Bao-Vi Nguyen; Freddy Yin Chiang Boey; Subbu S Venkatraman; Marcelle Machluf
Journal:  Tissue Eng Part A       Date:  2013-01-16       Impact factor: 3.845

5.  Differentiation of umbilical cord lining membrane-derived mesenchymal stem cells into endothelial-like cells.

Authors:  Chinh Chung Doan; Thanh Long Le; Nghia Son Hoang; Ngoc Trung Doan; Van Dong Le; Minh Si Do
Journal:  Iran Biomed J       Date:  2014

6.  Vascularization in tissue engineering: fundamentals and state-of-art.

Authors:  Guang Yang; Bhushan Mahadik; Ji Young Choi; John P Fisher
Journal:  Prog Biomed Eng (Bristol)       Date:  2020-01-09

Review 7.  Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy.

Authors:  Jinglian Yan; Guodong Tie; Ting Yu Xu; Katharine Cecchini; Louis M Messina
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

8.  Large-scale expansion of Wharton's jelly-derived mesenchymal stem cells on gelatin microbeads, with retention of self-renewal and multipotency characteristics and the capacity for enhancing skin wound healing.

Authors:  Guifang Zhao; Feilin Liu; Shaowei Lan; Pengdong Li; Li Wang; Junna Kou; Xiaojuan Qi; Ruirui Fan; Deshun Hao; Chunling Wu; Tingting Bai; Yulin Li; Jin Yu Liu
Journal:  Stem Cell Res Ther       Date:  2015-03-19       Impact factor: 6.832

Review 9.  Cell Therapy in Patients with Critical Limb Ischemia.

Authors:  Rita Compagna; Bruno Amato; Salvatore Massa; Maurizio Amato; Raffaele Grande; Lucia Butrico; Stefano de Franciscis; Raffaele Serra
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

10.  Clinical Observation of Employment of Umbilical Cord Derived Mesenchymal Stem Cell for Juvenile Idiopathic Arthritis Therapy.

Authors:  Liming Wang; Yu Zhang; Hongtao Li; Jingxin Hong; Xiaobo Chen; Ming Li; Wen Bai; Jiangang Wang; Yongjun Liu; Mingyuan Wu
Journal:  Stem Cells Int       Date:  2015-12-06       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.